OncoMatch/Clinical Trials/NCT03697356
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
Is NCT03697356 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lenalidomide, Bortezomib, Rituximab, Dexamethasone for waldenström's macroglobulinemia.
Treatment: Lenalidomide, Bortezomib, Rituximab, Dexamethasone — A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia (Ballondor trial)
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: (rituximab, lenalidomide, bortezomib)
Patients who have received rituximab, lenalidomide, or bortezomib
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1,000 / μL; Platelet count ≥75,000 cells / μL when not transfused
Kidney function
Renal failure requiring hemodialysis or peritoneal dialysis [excluded]
Liver function
Serum AST / ALT ≤ 3 times the upper limit of normal
Cardiac function
Patients with uncontrolled severe heart disease [excluded]; Patients with acute diffuse invasive pulmonary disease and cardiovascular disease [excluded]
Appropriate bone marrow, liver, and kidney function; Absolute neutrophil count (ANC) <1,000 / μL [excluded]; Platelet count <75,000 cells / μL when not transfused [excluded]; Serum AST / ALT> 3 times the upper limit of normal [excluded]; Renal failure requiring hemodialysis or peritoneal dialysis [excluded]; Patients with uncontrolled severe heart disease [excluded]; Patients with acute diffuse invasive pulmonary disease and cardiovascular disease [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify